Cocoon Bioscience SL
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cocoon Bioscience SL - overview
Established
2022
Location
-, -, Spain
Primary Industry
Biotechnology
About
Based in Spain, and founded in 2022, Cocoon Bioscience SL operates as a biotech firm that provides bioactive proteins and specialized enzymes for the healthcare industry. The company is a spun out of the biotech company Algenex. In March 2023, Cocoon Bioscience raised EUR 15 million in venture funding led by Cleon Capital, North South Ventures, and Viscofan. As of 2023, the company’s CEO is Joshua T.
Robinson. Cocoon Bioscience offers bioactive proteins and specialized enzymes for the food and healthcare industries. The company’s product line includes the CrisBio® platform, a biotech platform that utilizes Baculovirus Expression Vector Systems (BEVS) for protein production, mainly alternative enzymes and specialty enzymes. The company plans to use the funds raised in March 2023 to rapidly scale to industrial scale.
Current Investors
Viscofan, Columbus Venture Partners, Cleon Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.cocoonbioscience.com
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.